TABLE 4

Treatment strategies for IE due to non-HACEK GNB

Antibiotic therapyaNo. (% of totalb)
Noncarbapenem β-lactamc ± aminoglycosides ± fluoroquinolones29 (50)
    Penicillin or cephalosporin only5
    Non-carbapenem β-lactam + aminoglycosides14
    Non-carbapenem β-lactam + fluoroquinolones8
    Non-carbapenem β-lactam + aminoglycosides + fluoroquinolones2
Carbapenem ± aminoglycosides ± fluoroquinolones8 (13.8)
    Carbapenem only3
    Carbapenem + aminoglycosides1
    Carbapenem + fluoroquinolones3
    Carbapenem + aminoglycosides + fluoroquinolones1
Noncarbapenem β-lactam +carbapenem ± aminoglycosides ± fluoroquinolones13 (22.4)
    Non-carbapenem β-lactam + carbapenem4
    Non-carbapenem β-lactam + carbapenem + aminoglycosides3
    Non-carbapenem β-lactam + carbapenem + fluoroquinolones4
    Non-carbapenem β-lactam + carbapenem + aminoglycosides + fluoroquinolones2
Colistin-containing regimens3 (5.2)
    Colistin + carbapenem + rifampin2
    Colistin + penicillin or cephalosporin + carbapenem + rifampin1
Other regimens5 (8.6)
    Non-carbapenem β-lactam + rifampin1
    Non-carbapenem β-lactam + tobramycin + clindamycin1
    Aminoglycosides + rifampin1
    Aminoglycosides + fluoroquinolones + rifampin2
  • a ±, with or without.

  • b A total of 58 patients with IE due to non-HACEK GNB were studied.

  • c Includes penicillin alone, penicillin–penicillinase inhibitor combinations, and third-generation cephalosporins.